Found: 96
Select item for more details and to access through your institution.
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
- Published in:
- Oncologist, 2024, v. 29, n. 4, p. e514, doi. 10.1093/oncolo/oyad338
- By:
- Publication type:
- Article
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 3, p. 400, doi. 10.1002/cncr.35063
- By:
- Publication type:
- Article
Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 3, p. 1, doi. 10.1002/cam4.6877
- By:
- Publication type:
- Article
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.
- Published in:
- Oncologist, 2023, v. 28, n. 12, p. 1100, doi. 10.1093/oncolo/oyad158
- By:
- Publication type:
- Article
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 107, doi. 10.1007/s00280-023-04545-4
- By:
- Publication type:
- Article
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 14, p. 2201, doi. 10.1002/cncr.34773
- By:
- Publication type:
- Article
BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-022-00341-0
- By:
- Publication type:
- Article
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36399-y
- By:
- Publication type:
- Article
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36399-y
- By:
- Publication type:
- Article
Manufacturing‐dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development.
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 11, p. 2625, doi. 10.1111/cts.13387
- By:
- Publication type:
- Article
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology.
- Published in:
- NPJ Precision Oncology, 2022, v. 6, n. 1, p. 1, doi. 10.1038/s41698-022-00317-0
- By:
- Publication type:
- Article
Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-16588-3
- By:
- Publication type:
- Article
Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 7, p. 3392, doi. 10.1111/bcp.15294
- By:
- Publication type:
- Article
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-12669-5
- By:
- Publication type:
- Article
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 2, p. 290, doi. 10.1007/s10637-021-01188-1
- By:
- Publication type:
- Article
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 99, doi. 10.1007/s10637-021-01153-y
- By:
- Publication type:
- Article
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 124, doi. 10.1007/s10637-021-01184-5
- By:
- Publication type:
- Article
Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 2, p. 340, doi. 10.1002/cam4.4446
- By:
- Publication type:
- Article
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2021, v. 88, n. 5, p. 825, doi. 10.1007/s00280-021-04329-8
- By:
- Publication type:
- Article
A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 5, p. 1324, doi. 10.1007/s10637-021-01104-7
- By:
- Publication type:
- Article
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 5, p. 1357, doi. 10.1007/s10637-021-01119-0
- By:
- Publication type:
- Article
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
First‐in‐human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1047, doi. 10.1007/s10637-021-01081-x
- By:
- Publication type:
- Article
The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors.
- Published in:
- Clinical Pharmacokinetics, 2021, v. 60, n. 7, p. 921, doi. 10.1007/s40262-020-00983-y
- By:
- Publication type:
- Article
Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors.
- Published in:
- Oncologist, 2021, v. 26, n. 7, p. 558, doi. 10.1002/onco.13682
- By:
- Publication type:
- Article
Patient‐Reported Out‐of‐Pocket Costs and Financial Toxicity During Early‐Phase Oncology Clinical Trials.
- Published in:
- Oncologist, 2021, v. 26, n. 7, p. 588, doi. 10.1002/onco.13767
- By:
- Publication type:
- Article
Overview of Ocular Side Effects of Selinexor.
- Published in:
- Oncologist, 2021, v. 26, n. 7, p. 619, doi. 10.1002/onco.13756
- By:
- Publication type:
- Article
A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies.
- Published in:
- OncoTargets & Therapy, 2021, v. 14, p. 3037, doi. 10.2147/OTT.S291801
- By:
- Publication type:
- Article
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study.
- Published in:
- NPJ Precision Oncology, 2021, v. 5, n. 1, p. 1, doi. 10.1038/s41698-021-00159-2
- By:
- Publication type:
- Article
Associations between the gut microbiome and fatigue in cancer patients.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-84783-9
- By:
- Publication type:
- Article
Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Dose‐escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF‐mutated advanced cancers.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 3, p. 391, doi. 10.1002/cncr.33242
- By:
- Publication type:
- Article
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies.
- Published in:
- International Journal of Cancer, 2020, v. 147, n. 8, p. 2190, doi. 10.1002/ijc.33013
- By:
- Publication type:
- Article
Factors affecting symptom presentation in an early-phase clinical trials clinic patient population.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 4, p. 1166, doi. 10.1007/s10637-019-00879-0
- By:
- Publication type:
- Article
Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.
- Published in:
- Experimental Hematology & Oncology, 2020, v. 9, n. 1, p. 1, doi. 10.1186/s40164-020-00159-1
- By:
- Publication type:
- Article
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
- Published in:
- JNCI Cancer Spectrum, 2020, v. 4, n. 2, p. 1, doi. 10.1093/jncics/pkz093
- By:
- Publication type:
- Article
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine.
- Published in:
- Journal of Hematology & Oncology, 2019, v. 12, n. 1, p. 1, doi. 10.1186/s13045-019-0835-1
- By:
- Publication type:
- Article
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 638, doi. 10.1007/s10637-017-0534-0
- By:
- Publication type:
- Article